Mon, May 12, 12:31 PM (68 days ago)
**Lixte Biotechnology Holdings, Inc. (LIXT) Q1 2025 Financial Summary** **Financial Health:** - **Revenue:** $0 (no revenue generated). - **Net Loss:** $709,555 (Q1 2024: $971,322). - **Cash Position:** $1,384,697 (March 31, 2025). - **Operating Cash Flow:** -$568,483 (Q1 2025). **Performance Metrics:** - **Gross Margin:** Not applicable (no revenue). - **Operating Margin:** -100% (loss from operations/$0 revenue). - **Net Margin:** -100% (net loss/$0 revenue). **Profit Margins:** - **Operating Profit Margin:** Negative due to operating loss. - **Net Profit Margin:** Negative due to net loss. **Cash Flow:** - **Operating Cash Flow:** -$568,483 (Q1 2025). - **Investing Cash Flow:** $0 (Q1 2025). - **Financing Cash Flow:** $914,228 (Q1 2025, from equity offering). **Earnings Changes:** - **Quarter-over-Quarter:** Net loss decreased by $261,767. - **Year-over-Year:** Not applicable (no comparable data). **Quarterly Performance:** - **Revenue Growth:** N/A (no revenue). - **Earnings Growth:** Net loss decreased by 26.95%. **Trends & Uncertainties:** - **Revenue Trends:** No revenue generated. - **Earnings Trends:** Decreasing net loss. - **Uncertainties:** Dependence on equity financing, regulatory approvals, and clinical trial outcomes. **Future Operations Impact:** - **Cash Burn Rate:** High, with significant operating losses. - **Funding Needs:** Requires additional capital to sustain operations. - **Strategic Initiatives:** Focus on clinical trials and regulatory approvals. **Nasdaq Compliance:** - **Stock Price:** At risk of delisting due to minimum bid price requirement. - **Equity Requirements:** Must meet minimum stockholders' equity of $2,500,000 by July 3, 2025. **Clinical Trials:** - **Ongoing Trials:** LB-100 in combination with other drugs for various cancers. - **Financial Commitments:** $514,000 in remaining contractual commitments. **Risks:** - **Serious Adverse Events:** Potential clinical holds or trial terminations. - **Market Risks:** Dependence on equity financing and regulatory approvals. **Outlook:** - **Revenue Projections:** Uncertain, dependent on successful clinical trials and regulatory approvals. - **Earnings Projections:** Continued losses expected until revenue generation. - **Cash Flow Projections:** Negative operating cash flow, reliant on financing activities.